ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities

March 7, 2003

NCI Funds Proteomic Technology Assessment Grants.

September 29, 2006

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

April 16, 2004

Leukemia Society Accepting Grant Applications for ‘88

May 22, 1987

Celgene Signs CRADA With NCI For Development Of CDC-501.

June 30, 2000

In Brief: Hopkins Wins SPORE in Gastointenstinal Cancers; Nurses Group Calls For Proposals

January 21, 1994